Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Moberg Derma Ab (MBGRF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance

Most Recent Stories

More News
Proposed Management Changes at Moberg Pharma

Moberg Pharma AB (OMX: MOB) has a nimbler organization following the divestment of its OTC business, and intends to adapt the leadership accordingly. The Board of Directors and Nomination Committee have...

MBGRF : 6.9900 (unch)
Proposed Management Changes at Moberg Pharma

STOCKHOLM , April 8, 2019 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) has a nimbler organization following the divestment of its OTC business, and intends to adapt the leadership accordingly....

MBGRF : 6.9900 (unch)
Moberg Pharma: The Nomination Committee's Proposal to the Annual General Meeting 2019

STOCKHOLM , April 8, 2019 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) announces that the company's Nomination Committee has decided to present the following proposal to the Annual General Meeting...

MBGRF : 6.9900 (unch)
Moberg Pharma: The Nomination Committee's Proposal to the Annual General Meeting 2019

Moberg Pharma AB (OMX: MOB) announces that the company's Nomination Committee has decided to present the following proposal to the Annual General Meeting 2019.

MBGRF : 6.9900 (unch)
RoundTable Healthcare Partners and Signet Healthcare Partners Establish New Platform in the Global Consumer Healthcare Market

RoundTable Healthcare Partners ("RoundTable"), an operating-oriented private equity firm focused exclusively on the healthcare industry, and Signet Healthcare Partners ("Signet"), an established provider...

MBGRF : 6.9900 (unch)
Moberg Pharma Gives Notice of Early Redemption of Bonds With ISIN SE0007953989

STOCKHOLM , April 1, 2019 /PRNewswire/ -- On February 12th, 2019 , it was announced that Moberg Pharma AB (publ) ("Moberg Pharma" or the "Company") has entered into agreement with RoundTable...

MBGRF : 6.9900 (unch)
Moberg Pharma Completes the Divestment of the OTC-business for USD 155 million

Moberg Pharma AB (publ) ("Moberg Pharma" or the "Company") has today completed the divestment of its OTC-business (over-the-counter) to RoundTable Healthcare Partners and Signet Healthcare Partners (the...

MBGRF : 6.9900 (unch)
Moberg Pharma Completes the Divestment of the OTC-business for USD 155 million

STOCKHOLM , March 29, 2019 /PRNewswire/ -- Moberg Pharma AB (publ) ("Moberg Pharma" or the "Company") has today completed the divestment of its OTC-business (over-the-counter) to RoundTable...

MBGRF : 6.9900 (unch)
Moberg Pharma Completes Enrollment for MOB-015 Phase 3 Study in Europe

Moberg Pharma AB (OMX: MOB) has completed the recruitment of 452 patients with onychomycosis (nail fungus) for the ongoing MOB-015 phase 3 study in Europe. Two Phase 3-studies are currently underway in...

MBGRF : 6.9900 (unch)
Moberg Pharma Completes Enrollment for MOB-015 Phase 3 Study in Europe

STOCKHOLM , March 22, 2019 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) has completed the recruitment of 452 patients with onychomycosis (nail fungus) for the ongoing MOB-015 phase 3 study in...

MBGRF : 6.9900 (unch)
Trade MBGRF with:

Key Turning Points

2nd Resistance Point N/A
1st Resistance Point N/A
Last Price 6.9900
1st Support Level N/A
2nd Support Level N/A

See More

52-Week High 6.9900
Fibonacci 61.8% 6.9900
Fibonacci 50% 6.9900
Fibonacci 38.2% 6.9900
Last Price 6.9900
52-Week Low 6.9900

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar